Publications

Activity of Fusidic Acid against Recent Clinical Isolates of Staphylococci Collected from United States Hospitals in 2016 as Part of the SENTRY Antimicrobial Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-56

In Vitro Activity of LYS228 against Enterobacteriaceae, Including Molecularly Characterized Multidrug-Resistant Isolates. Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-293

Fosfomycin Activity When Tested against Gram-Positive and Gram-Negative US Isolates Collected by the SENTRY Antimicrobial Surveillance Program. Lead author: R Flamm, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-57

Correlation of Reference Agar Dilution MIC Values and Kirby-Bauer Disk Diffusion Testing for Fosfomycin against Gram-Positive and Gram-Negative Bacteria. Lead author: R Flamm, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-411

Time Kill Analyses of Concerning Gram-Negative Bacteria with Fosfomycin Alone and in Combination with Select Antimicrobial Agents. Lead author: R Flamm, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-414

Meropenem-Vaborbactam Activity against Enterobacteriaceae Isolates, Including Carbapenem-Resistant and Carbapenemase-Producing Isolates, Collected in United States (US) Hospitals During 2016. Lead author: M Castanheira, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-58

Tedizolid Activity against Gram-Positive Clinical Isolates Causing Bone and Joint Infections, Including Osteomyelitis in United States and European Hospitals (2014-2016). Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-341

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2014-2016) Pseudomonas aeruginosa Isolates with Various Resistant Phenotypes from US Hospitals. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-50

Serotype Distributions and Analysis of Susceptibility Profiles of Streptococcus pneumoniae Causing Infections in Adult Patients in the United States (2009-2015). Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-129

Meropenem-Vaborbactam (Carbavance^TM) MIC and Zone Diameter Quality Control Ranges Using a CLSI M23-A4 Multi-Laboratory Study Design. Lead author: M Huband, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
#Friday-417

Antimicrobial Activity of Cefepime-Zidebactam (WCK 5222) When Tested against Bacterial Isolates from Patients Hospitalized with Pneumonia. Lead author: H Sader, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
#Friday-52

Susceptibility of Ceftolozane-Tazobactam against Isolates Collected from Intensive Care Unit Patients in US Hospitals from 2014-2016. Lead author: M Pfaller, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-76

Time Kill Analyses of Concerning Gram-Negative Bacteria with Fosfomycin Alone and in Combination with Select Antimicrobial Agents. Lead author: R Flamm, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-414

Impact of Changes in Growth Medium, Inoculum Density, and Incubation Conditions on the In Vitro Antimicrobial Activity of Plazomicin. Lead author: L Duncan presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-410

In Vitro Activity and Potency of the Novel Oxazolidinone MRX-I Tested against Contemporary Clinical Isolates of Gram-Positive Bacteria. Lead author: H Sader, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
#Friday-343

Oritavancin In Vitro Activity Against a Collection of Gram-Positive Clinical Isolates Causing Bone and Joint Infections, Including Osteomyelitis, in United States and European Hospitals (2012-2016). Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-342

Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Isolates Harboring β-Lactamase Genes Detected Using Whole Genome Sequencing Analysis. Lead author: M Castanheira, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-57

Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Infections in United States Hospitals (2014-2016). Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-340

WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against gram-negative organisms producing clinically relevant beta-lactamases. by Sader HS, Rhomberg PR, Flamm RK, Jones RN and Castanheira M published in J. Antimicrob. Chemother. 2017; 72 (6): 1696-1703

Pseudomonas aeruginosa antimicrobial susceptibility results from four years (2012-2015) of the International Network for Optimal Resistance Monitoring program in the United States. by Sader HS, Huband MD, Castanheira M and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (3): e02252

Antimicrobial activity of high-proportion cefepime-tazobactam (WCK 4282) against a large number of gram-negative isolates collected worldwide in (2014). by Sader HS, Castanheira M, Mendes RE, Flamm RK and Jones RN published in Antimicrob. Agents. Chemother. 2017; 61 (4): e02409

Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014). by Sader HS, Castanheira M, Jones RN and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2017; 87 (3): 261-265

WCK 5222 (cefepime-zidebactam) antimicrobial activity tested against clinical isolates of gram-negative bacteria collected worldwide (2015). by Sader HS, Castanheira M, Huband M, Jones RN and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (5): 00072

Antimicrobial activity of ceftazidime-avibactam against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2011-2015). by Sader HS, Castanheira M and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (4): e02083

Activities of omadacycline and comparator agents when tested against Staphylococcus aureus from a surveillance program conducted in North America and Europe. by Pfaller MA, Rhomberg PR, Huband MD and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (3): e02411

Activity of a long-acting Echinocandin (CD101) and seven comparator antifungal agents tested against a global collection of contemporary invasive fungal isolates in the SENTRY (2014) Antifungal Surveillance Program. by Pfaller MA, Messer SA, Rhomberg PR and Castanheira M published in Antimicrob. Agents Chemother. 2017; 61 (3): e02045

Ceftaroline activity against multidrug-resistant Streptococcus pneumoniae from U.S. Medical Centers (2014) and molecular characterization of a single ceftaroline nonsusceptible isolate. by Pfaller MA, Mendes RE, Flamm RK, Jones RN and Sader HS published in Microb. Drug Resist. 2017; 23 (5): 571-579

Ceftaroline activity tested against bacterial isolates causing community-acquired respiratory tract infections and skin and skin structure infections in pediatric patients from United States hospitals: 2012-2014. by Pfaller MA, Mendes RE, Castanheira M, Flamm RK, Jones RN and Sader HS published in Pediatr. Infect. Dis. J. 2017; 36 (5): 486-491

Surveillance of omadacycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Western Pacific) collection (2010-2011). by Pfaller MA, Huband MD, Rhomberg PR and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (5): e00018-00017

Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013-2014). by Pfaller MA, Flamm RK, Duncan LR, Mendes RE, Jones RN and Sader HS published in Diagn. Microbiol. Infect. Dis. 2017; 88 (2): 177-183

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: Report from an antimicrobial surveillance programme (2012-15). by Pfaller MA, Bassetti M, Duncan LR and Castanheira M published in J. Antimicrob. Chemother. 2017; 72 (5): 1386-1395

Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011-2014). by Mendes RE, Sader HS, Smart JI, Castanheira M and Flamm RK published in Eur. J. Clin. Microbiol. Infect. Dis. 2017; 36 (6): 1013-1017

Molecular beta-lactamase characterization of aerobic Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials for complicated intra-abdominal infections, with efficacies analyzed against susceptible and resistant subsets. by Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (6): e02447-16

Prevalence of macrolide-lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents. by Mendes RE, Castanheira M, Farrell DJ, Flamm RK, Sader HS and Jones RN published in J. Glob. Antimicrob. Resist. 2017; 8: 28-32

Impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam/beta-lactam combinations. by McLeod SM, Patey SA, Huband MD and Nichols WW published in Int. J. Antimicrob. Agents. 2017; 49 (4): 437-442

Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. by Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, Colombo AL, Calvo B, Cuomo CA, Desjardins CA, Berkow EL, Castanheira M, Magobo RE, Jabeen K, Asghar RJ, Meis JF, Jackson B, Chiller T and Litvintseva AP published in Clin. Infect. Dis. 2017; 64 (2): 134-140

Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations. by Jones RN, Flamm RK, Castanheira M, Sader HS, Smart JI and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2017; 88 (2): 184-187

Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design. by Huband MD, Ito A, Tsuji M, Sader HS, Fedler KA and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2017; 88 (2): 198-200

Effect of susceptibility testing conditions on the in vitro antibacterial activity of ETX0914. by Giacobbe RA, Huband MD, deJonge BL and Bradford PA published in Diag. Microbio. Infect. Dis. 2017; 87 (2): 139-142

In vitro activity of gepotidacin (GSK2140944) against Neisseria gonorrhoeae. by Farrell DJ, Sader HS, Rhomberg PR, Scangarella-Oman NE and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (3): e02047

Empyema thoracis caused by an optrA-positive and linezolid-intermediate Enterococcus faecalis strain. by Chien JY, Mendes RE, Deshpande LM and Hsueh PR published in J. Infect. 2017; 75 (2): 182-184

Low frequency of ceftazidime-avibactam resistance among Enterobacteriaceae isolates carrying bla_KPC collected in U.S. hospitals from 2012 to 2015. by Castanheira M, Mendes RE and Sader HS published in Antimicrob. Agents Chemother. 2017; 61 (3): e02369

Pseudomonas aeruginosa bacteremic patients exhibit nonprotective antibody titers against therapeutic antibody targets PcrV and Psl exopolysaccharide. by Thaden JT, Keller AE, Shire NJ, Camara MM, Otterson L, Huband M, Guenther CM, Zhao W, Warrener P, Stover CK, Fowler VG, Jr. and DiGiandomenico A published in J. Infect. Dis. 2016; 213 (4): 640-648

Voriconazole minimum inhibitory concentrations are predictive of treatment outcome in experimental murine infections by Candida glabrata. by Sanchis M, Capilla J, Castanheira M, Martin-Vicente A, Sutton DA, Fothergill AW, Wiederhold NP and Guarro J published in Int. J. Antimicrob. Agents. 2016; 47 (4): 286-288

In vivo emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis. by Sanchez EH, Mendes RE, Sader HS and Allison GM published in J. Antimicrob. Chemother. 2016; 71 (6): 1736-1738

Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline Surveillance Program (2012-2014). by Sader HS, Mendes RE, Jones RN and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2016; 86 (1): 76-79

Antimicrobial activities of ceftazidime-avibactam and comparator agents against Gram-negative organisms isolated from patients with urinary tract infections in U.S. Medical Centers, 2012 to 2014. by Sader HS, Castanheira M, Flamm RK and Jones RN published in Antimicrob. Agents. Chemother. 2016; 60 (7): 4355-4360

Ceftazidime-avibactam activity against aerobic Gram negative organisms isolated from intra-abdominal infections in United States hospitals, 2012-2014. by Sader HS, Castanheira M, Flamm RK, Huband MD and Jones RN published in Surg. Infect. (Larchmt). 2016; 17 (4): 473-478

Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: Results from SENTRY Antimicrobial Surveillance Program (2011-2014). by Sader HS, Castanheira M, Farrell DJ, Flamm RK, Mendes RE and Jones RN published in Int. J. Antimicrob. Agents. 2016; 48 (2): 144-150

Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates. by Pfaller MA, Messer SA, Rhomberg PR, Jones RN and Castanheira M published in J. Antimicrob. Chemother. 2016; 71 (10): 2868-2873